The company has received approval from DCGI to begin patient enrolment and dosing in the country
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Replicate will receive research funding and could potentially receive up to approximately US$550 million
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
The company is bringing precision therapies for gynaecological cancers
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Subscribe To Our Newsletter & Stay Updated
